Yin DT, et al. - In order to evaluate the association of telomerase reverse transcriptase (TERT) promoter mutation and aggressive clinical behaviors in papillary thyroid carcinoma (PTC), a systematic review and meta-analysis of published literature were conducted. For relevant studies, they conducted a systematic search in PubMed, EMBASE, OVID and Web of Science databases. Two thousand, thirty-five patients were included in the analysis in eight eligible trials. They found that the average TERT promoter mutation prevalence was 10.32%. According to findings, TERT promoter mutation-positive PTC is more likely to show aggressive clinicopathological features. Testing for the TERT promoter mutation is likely to be helpful in supporting risk stratification and management of PTC in appropriate clinical settings. The TERT promoter mutation was correlated with male gender, lymph node metastasis, extrathyroidal extension, distant metastasis, advanced TNM stage III/IV, poor clinical outcome and mortality vs the wild-type TERT promoter gene.